Orchid Pharma Board Meeting on August 14, 2026

Orchid Pharma Limited

This is a regulatory disclosure submitted under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Board of Directors of Orchid Pharma Limited is scheduled to meet on Friday, August 14, 2026.

The primary agenda for the board meeting includes:

• Consideration and approval of the Unaudited Limited Reviewed Financial Results (Standalone & Consolidated) for Quarter 1 of Financial Year 2026-27, ended June 30, 2026.
• Consideration and approval of the Restated Audited Standalone & Consolidated Financial Results for the quarter and financial year ended March 31, 2026. This restatement includes the restated statement of assets & liabilities, restated cash flow statement, and revised auditors' reports issued by the company's statutory auditors, M/s. Singhi & Co. The restatement is required on account of a Scheme of Amalgamation coming into effect.

The disclosure also confirms the continuation of the Trading Window closure for dealing in the company's securities. The window was closed commencing July 1, 2026, and will remain closed until 48 hours after the declaration of the aforementioned Unaudited Limited Reviewed Results for Q1 FY27.